Lyme borreliosis diagnosis: state of the art of improvements and innovations

BMC Microbiology

Table 2 Examples of sensitivity and specificity for MTTT in America and in Europe

Methods used		Symptoms / Stage of the disease	Patient's localization
Methods used			America			Europe
First test	Second test		Sensitivity	Specificity	References	Sensitivity	Specificity	References
VlsE C6-ELISA	na	Erythema migrans or early Lyme borreliosis AP	29%	96%	[68]	65–68%	91–92%	[34, 61]
		Erythema migrans or early Lyme borreliosis CP	56%	96%		80–82%
		Acute-phase neurologic or cardiac involvement	98–100%	96%		94–100%
		Arthritis or late neurologic involvement	98–100%	96%		94–100%
Enzygnost-2®	C6-ELISA	Erythema migrans or early Lyme borreliosis	na			78%	96%	[59]
Whole-Cell Sonicate ELISA	C6-ELISA	Erythema migrans or early Lyme borreliosis AP	38–58%	98–100%	[20, 34]	na
Whole-Cell Sonicate ELISA	C6-ELISA	Erythema migrans or early Lyme borreliosis CP	76–79%	98–100%	[20, 34]
Borrelia DotBlot G®	na	nd	93%	35%	[69]
MarDx® EIA	na		100%	92%
VIDAS®	na		100%	90%
VlSE1-IgG	pepC10-IgM	Erythema migrans or early Lyme borreliosis AP	46%	96%	[54]
		Erythema migrans or early Lyme borreliosis CP	89%
		Acute-phase neurologic or cardiac involvement	100%
		Arthritis or late neurologic involvement	100%
VlsE1-pepC10	C6-ELISA	Erythema migrans or early Lyme borreliosis AP	na			51%	94–95%	[61]
		Erythema migrans or early Lyme borreliosis CP				67%
		Acute-phase neurologic or cardiac involvement				88%
		Arthritis or late neurologic involvement				90%

ISSN: 1471-2180